129例奥氮平药品不良反应及血药浓度监测临床分析

doi:10.19803/j.1672-8629.2020.11.15

中国药物警戒 ›› 2020, Vol. 17 ›› Issue (11): 818-822.
DOI: 10.19803/j.1672-8629.2020.11.15

129例奥氮平药品不良反应及血药浓度监测临床分析

曾环思¹, 钟彩妮^2,*, 钟易霖¹, 彭陈陈¹, 张璇¹

¹深圳市康宁医院研究所,广东深圳 518020;
²深圳市康宁医院药学部,广东深圳 518020

收稿日期:2020-11-10 修回日期:2020-11-10 出版日期:2020-11-15 发布日期:2020-11-10
通讯作者: ^*钟彩妮,女,本科,主管药师,临床药学。E-mail：zcn6615@21cn.com
作者简介:曾环思,男,硕士,副主任药师,临床药学及药理学。
基金资助:
广东省高水平临床重点专科（深圳市配套建设经费）资助（SZGSP013）; 深圳市卫生计生系统科研项目（SZFZ2018039）深圳市科技计划项目（JCYJ20150402093137766）

Analysis of 129 Cases of Adverse Reactions and Clinical Application of Plasma Concentration Monitoring of Olanzapine

ZENG Huansi¹, ZHONG Caini^2,*, ZHONG Yilin¹, PENG Chenchen¹, ZHANG Xuan¹

¹Institute of Pharmacy, Shenzhen Kangning Hospital, Shenzhen Guangdong 518020, China;
²Department of Pharmacy, Shenzhen Kangning Hospital, Shenzhen Guangdong 518020, China

Received:2020-11-10 Revised:2020-11-10 Online:2020-11-15 Published:2020-11-10

摘要/Abstract

摘要： 目的分析奥氮平药品不良反应及血药浓度监测的临床应用,为临床合理用药提供参考。方法分析2017年1月至2019年6月深圳市康宁医院上报129例奥氮平药品不良反应(ADR)报告,探讨患者性别、年龄、剂量、合并用药及血药浓度及浓度/剂量比值（C/D）与奥氮平ADR的关系。结果 129例奥氮平ADR主要为神经精神系统损害、肝胆系统损害及心血管系统损害,以肝功能异常、锥体外系反应和静坐不能最为常见;患者年龄以19~40岁居多,女性患者ADR报告多于男性,男性发生严重ADR占比高于女性（P<0.05）;联合用药发生严重ADR比率与单一用药无显著性差异（P>0.05）;72.87%患者在ADR发生期间监测了血药浓度,严重ADR血药浓度及C/D值与一般不良反应无显著性差异（P>0.05）。结论临床应用奥氮平时应加强其ADR监测和治疗药物监测,减少合并用药,保障临床用药安全。

关键词: 奥氮平, 药品不良反应, 血药浓度, 合并用药

Abstract: Objective To analyze the adverse drug reactions (ADR) and plasma concentration monitoring of olanzapine so as to provide reference for clinical rational use of drugs. Methods A retrospective analysis of 129 cases of ADR by Shenzhen Kangning Hospital from January 2017 to June 2019 induced by olanzapine was conducted to explore the relationships between the patients' gender, age, dosage, drug combination, plasma concentration and concentration-dosage ratio (C/D) and ADR of olanzapine. Results ADR mainly damaged the neuropsychiatric system, hepatobiliary system and cardiovascular system. The most common clinical manifestations were abnormal liver function, extrapyramidal diseases and akathisia. Most of the patients were aged 19 to 40. ADR reports involved more females than males, but in reports of serious ADR, males outnumbered females(P <0.05). There was no significant difference in the incidence of serious ADR between combined medication and single medication(P>0.05). 72.87% of the patients had their plasma concentrations monitored during the occurrence of ADR. There was no significant difference in the plasma concentration or C/D value between ADR and serious ADR(P>0.05). Conclusion When olanzapine is used in clinic, clinicians should strengthen the monitoring of ADR and therapeutic drugs, reduce drug combination, and ensure the safety of clinical drug use.

Key words: olanzapine, adverse drug reactions, plasma concentration, drug combination

中图分类号:

R994.11

曾环思, 钟彩妮, 钟易霖, 彭陈陈, 张璇. 129例奥氮平药品不良反应及血药浓度监测临床分析[J]. 中国药物警戒, 2020, 17(11): 818-822.

ZENG Huansi, ZHONG Caini, ZHONG Yilin, PENG Chenchen, ZHANG Xuan. Analysis of 129 Cases of Adverse Reactions and Clinical Application of Plasma Concentration Monitoring of Olanzapine[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 818-822.

参考文献

[1] Rojo LE, Gaspar PA, Silva H, et al.Metabolic Syndrome and Obesity among Users of Second Generation Antipsychotics: A Global Challenge for Modern Psychopharmacology[J]. Pharmacological Research, 2015, 101(11): 74-85.
[2] Zhang DL, Lu L, Yao P, et al.Analysis of 183 Cases of Adverse Drug Reactions Induced by Atypical Antipsychotropic Drugs[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2017, 14(2): 109-112.
[3] Barak N, Beck Y, Albeck JH.A randomized, double-blind, placebo-controlled pilot study of betahistine to counteract olanzapine-associated weight gain[J]. Journal of Clinical Psychopharmacology, 2016, 36(3): 253-256.
[4] Hiemke C, Bergemann N, Clement H, et al.Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017[J]. Pharmacopsychiatry, 2018, 51(1/2): 9-62.
[5] Ministry of Health of the People's Republic of China. Provisions for Adverse Drug Reaction Reporting and Monitoring(Order No. 81 of the Ministry of Health)[EB/OL]. (2011-05-04) [2018-10-28]. http://www.gov.cn/flfg/2011-05/24/content_1870110.htm.
[6] Zeng H S, Zhang X, Zhong CN, et al.Utilization of Antipsychotic Drugs in Our Hospital from 2012 to 2014[J]. China Pharmaceuticals(中国药业), 2016, 25(9): 73-76.
[7] Deng C.Effects of antipsychotic medications on appetite, weight, and insulin resistance[J]. Endocrinology and Metabolism Clinics, 2013, 42(3): 545-563.
[8] Song ME, Lu HY, Wang ZZ, et al.Retrospective Analysis of 302 Cases of Adverse Drug Reactions Induced by Olanzapine[J]. Pharmacy Today(今日药学), 2017, 27(5): 345-348.
[9] Ni W, Zhou HP, Huang ST, et al.Research Progress of Atypical Antipsychotic[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志), 2009, 29(18): 1570-1573.
[10] Detke HC, Weiden PJ, Llorca PM, et al.Comparison of olanzapine long-acting injection and oral olanzapine: a 2-year, randomized, open-label study in outpatients with schizophrenia[J]. Journal of Clinical Psychopharmacology, 2014, 34(4): 426-434.
[11] Wang J, Su MJ, Zhao XY, et al.Retrospective Analysis on 365 Cases of Adverse Drug Reactions in a Psychiatric Hospital[J]. Chinese Journal of pharmacovigilance(中国药物警戒), 2015, 12(9): 560-563.
[12] Telles-Correia D, Barbosa A, Cortez-Pinto H, et al.Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity[J]. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2017, 8(1): 26.
[13] Xia L, Li WZ, Liu HZ, et al.Olanzapine versus risperidone in children and adolescents with psychosis: a meta-analysis of randomized controlled trials[J]. Journal of Child and Adolescent Psychopharmacology, 2018, 28(4): 244-251.
[14] Sun ZX, Yu XF.Progress in studies on tardive dystonia induced by antipsychotic drugs[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2012, 14(1): 34-35.
[15] Hao JY, Chen BH, Qin TX, et al.Clinical Observation of Ziprasidone Combined with Olanzapine in the Treatment of Refractory Schizophre-nia in Elderly Patients[J]. China Pharmacy(中国药房), 2015, 26(33): 4652-4654.
[16] Zhou QJ, Wu XY, Qu FL.A case of measles-like drug eruption caused by olanzapine[J]. Chinese Journal of pharmacovigilance(中国药物警戒), 2012, 9(10): 639-640.
[17] Woon LS-C, Tee CK, Gan LLY, et al.Olanzapine-induced and risper-idone-induced leukopenia: a case of synergistic adverse reaction[J]. Journal of Psychiatric Practice®, 2018, 24(2): 121-124.

129例奥氮平药品不良反应及血药浓度监测临床分析

Analysis of 129 Cases of Adverse Reactions and Clinical Application of Plasma Concentration Monitoring of Olanzapine

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.